Archived tissue samples from people with t(4;14) multiple myeloma, studied for biomarkers
Checks whether stored samples from adults with t(4;14) multiple myeloma can reveal biomarkers.
Plain-language title generated from the registry record
Registry title: Multiple Myeloma t(4 ;14) FFPE Samples
Key facts
- Where
- Lyon, FranceSee the site
Where in France
- BIWAKOLyon, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- BIWAKO
- Trial code
- NCT07482761
- Record updated
- 19 March 2026
- Original description
This observational study aims to evaluate the feasibility of assembling a retrospective cohort of formalin-fixed paraffin-embedded (FFPE) tissue samples from patients with 4;14 translocated multiple myeloma, together with their associated clinical and pathological data. The study will determine whether these archived samples are suitable for exploratory biomarker assessment.Read full original descriptionShow less
Discovery And Validation Of New Biomarkers In The Context Of Multiple Myeloma With t(4-14) and Relapse
This observational study aims to evaluate the feasibility of assembling a retrospective cohort of formalin-fixed paraffin-embedded (FFPE) tissue samples from patients with 4;14 translocated multiple myeloma, together with their associated clinical and pathological data. The study will determine whether these archived samples are suitable for exploratory biomarker assessment.
No intervention is performed. All FFPE samples and clinical data originate exclusively from routine diagnostic procedures and will be analyzed retrospectively for research purposes.
Inclusion: Adult patients with histologically confirmed myeloma with a t(4;14) translocation; Availability of a representative FFPE block from a surgical specimen; Diagnosis established within the past 10 years; Availability of associated clinical and follow-up data.
Exclusion: Bone lesions samples; Insufficient or non-representative FFPE material; Missing key diagnostic or clinical data.